Australia's most trusted
source of pharma news
Tuesday, 24 June 2025
Posted 23 June 2025 AM
Most companies scored a recommendation at the PBAC’s May meeting, with 71 per cent of submissions given the nod – the same success rate seen at the previous March meeting.
Overall, the committee recommended 7 of 8 new PBS listing submissions and 8 of 11 change to existing listing submissions. Two new NIP listing submissions – Sanofi’s Beyfortus and Pfizer’s Comirnaty Omicron XBB.1.5 - were deferred along with one change to existing listing submission.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.